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Introduction: Antioxidants play an important role in counteracting
the effects of potential carcinogens. We investigated the risk of lung
cancer development with respect to manganese superoxide dis-
mutase (MnSOD) and catalase genetic polymorphisms and their
association with erythrocyte antioxidant activities.
Patients and Methods: This was a case-control study involving
patients with confirmed lung cancer and age-matched healthy con-
trols. Genotyping of MnSOD and catalase in DNA extracted from
peripheral white cells was performed by polymerase chain reaction-
based restriction fragment length polymorphism. Erythrocyte super-
oxide dismutase and catalase activities were measured spectropho-
tometrically using chemical kinetic reactions.
Results: We recruited 240 patients with lung cancer (63% male,
aged 55.6 11.9 years, 58% adenocarcinoma, 85% clinical stage III
or IV) and 240 age-matched healthy controls. The frequencies of the
Val allele of MnSOD gene and the C allele of catalase gene were
common (86% and 90%, respectively), with similar distribution,
in both patients with lung cancer and controls. The homozygous
variant genotypes of MnSOD and catalase were not associated with
increased lung cancer risk. The erythrocyte SOD and catalase
activity was significantly lower among all patients with lung cancer
as a whole compared with controls, irrespective of genotypes.
However, patients with adenocarcinoma and non-adenocarcinoma
showed differences in SOD and catalase activity among different
genotypes in comparison with controls.
Conclusion: The common Val16Ala MnSOD polymorphism and
C-T substitution in the promoter region of the catalase gene do not
confer increased or reduced risk of lung cancer in Chinese in Hong
Kong.
Key Words: Antioxidants, Genetic susceptibility, Carcinoma of
lung.
(J Thorac Oncol. 2006;1: 648–653)
Reactive oxygen species (ROS) have been implicated inmany diseases, including cancer, by causing DNA dam-
age and spontaneous chromosomal breakage and activating
procarcinogens.1 Tobacco smoke, the single most important
cause of lung cancer, is a major source of exogenous ROS in
the lungs of smokers2; it is also responsible for endogenous
ROS production by causing airway inflammation and accu-
mulation of neutrophils in the airways and the lungs.3 The
body has a very effective network of antioxidants serving as
scavengers of superoxide and hydrogen peroxide, including
superoxide dismutase (SOD), catalase (CAT), and glutathi-
one peroxidase (GPx).1 SOD is one of the key enzymes that
detoxifies the superoxide radical (O2
) and generates hydro-
gen peroxide (H2O2), which in turn is detoxified by catalase
and GPx. Of the three forms of SOD in humans, mitochon-
drial manganese SOD (MnSOD) may be particularly impor-
tant for antioxidant defense as the mitochondria are the major
site for cellular metabolism and the main site for the produc-
tion of ROS.4
As only a small proportion of smokers develop lung
cancer, individual susceptibility is likely to be important in
the pathogenesis. Polymorphisms of genes leading to a re-
duction of antioxidant activities have been postulated to be a
possible mechanism. There is a polymorphic site identified in
the mitochondria targeting sequence of human MnSOD
gene.5 This C to T substitution results in an amino acid
change from valine (Val) to alanine (Ala) at codon 16, which
is predicted to form amphiphilic helix with higher enzyme
activity.5 MnSOD polymorphism (Val to Ala at codon 16)
has been found to increase the risk of lung cancer in a
Caucasian population6,7 but not in two Chinese popula-
tions.8,9 However, the prevalence of MnSOD polymorphism
is variable in different ethnic groups.5,10 So far, the relation-
ship between genetic polymorphism in the promoter at
C-262T of catalase gene from the transcription start site,
which has a substantial impact on both the basal expression of
catalase and the level of this enzyme in erythrocytes11 and the
risk of lung cancer, has not been investigated.
This is a case-control study evaluating the association
of the common Val16Ala MnSOD polymorphism and the
C-262T polymorphism of catalase gene and the risk of lung
cancer of Chinese in Hong Kong. Because MnSOD activity
accounts for approximately 90% of total SOD activity, we
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This is part of an ongoing, hospital-based lung cancer
case-control study initiated in 1999 at the Queen Mary
Hospital in Hong Kong, SAR, China. The study population
has been described previously.12 Consecutive patients with
histological or cytological confirmation of the diagnosis of
primary lung cancer were recruited. The healthy controls
were recruited as part of a population-based lung function
study in Hong Kong between July 1999 and March 2003.13
Individuals older than 18 years were recruited by telephone
using random digit dialing. None of the controls had a history
of lung cancer. Randomly selected controls were matched to
the cases by age ( 5 years). All patients and controls were
ethnically Chinese originating from Hong Kong or the
Guangdong province of Southern China. The percentage of
participation was 95% for the patients and 46% for the
controls. This study has the approval of the Ethics Commit-
tee, Faculty of Medicine, The University of Hong Kong.
Informed consent was obtained from each participant in the
study.
Questionnaire
Trained research assistants interviewed patients and
controls using a questionnaire to obtain the following infor-
mation: demographic data, smoking habits, presence or ab-
sence of chest symptoms, and history of chest diseases and
surgery and occupational exposure.
Genetic Studies
Venous blood (10 ml) was taken from each subject.
Red blood cells, buffy coat, and plasma were separated by
immediate centrifugation at 2500 rpm for 10 minutes and
stored at 70°C until subsequent assays. Genomic DNA was
extracted from peripheral white cells using the rapid non-
enzymatic method14 or commercially available QIAamp
DNA Blood Mini extraction kit (QIAGEN). Polymerase
chain reaction (PCR)-based restriction fragment length poly-
morphism (RFLP) was used to examine the polymorphisms
of interest. Genotyping of MnSOD and catalase was per-
formed using methods described in the literature.10,11
Measurement of Antioxidant Activity in
Erythrocytes
Red blood cell hemolysate was prepared by washing
packed red blood cells three times with cold normal saline
under centrifugation at 3000 g and then lysed with 4 volumes
of cold deionized water. Hemoglobin (Hb) concentrations
were assayed by a commercially available kit (Sigma, St.
Louis, MO).
Superoxide Dismutase Activity
SOD activity in red blood cell hemolysate was deter-
mined from the rate of reduction of cytochrome c,15 with 1 U
of SOD activity defined as the amount of SOD required to
inhibit the rate of cytochrome c reduction by 50%. Xanthine
oxidase (Sigma) was added at a concentration sufficient to
induce a 0.020 change in absorbance per minute at 550 nm.
The SOD activity was expressed as U/g Hb.
Catalase Activity
The quantification of catalase activity in the red blood
cell hemolysate was based on the reaction with hydrogen
peroxide as previously described.16 In brief, the initial rate of
disappearance of hydrogen peroxide (0 to 60 seconds) was
recorded spectrophotometrically at a wavelength of 240 nm.
One unit of catalase activity was defined as the rate constant
of the first-order reaction. The catalase activity was expressed
as U/g Hb.
Data Analysis
Ever-smokers were defined as those who had ever
smoked at least one cigarette a day for 1 year or more,
whereas nonsmokers were life-long nonsmokers who had
never smoked in their life or had smoked less than one
cigarette a day for 1 year. The characteristics of patients and
healthy controls were compared using 2 analysis or t test,
whichever was applicable. The frequency distribution of various
polymorphisms was checked separately in controls and patients
to verify Hardy-Weinberg equilibrium by SNPAnalyzer pro-
gram (Istech Inc., Goyang-si, Gyeonggi-do, Korea).
The prevalence of polymorphisms in healthy controls
and patients with lung cancer and the associations of these
polymorphisms with lung cancer were determined. Lung
carcinoma other than adenocarcinoma was defined as non-
adenocarcinoma; that is, squamous, small cell, large cell, and
other carcinoma. Unconditional logistic regression analysis
was used to generate odds ratios (OR) and 95% confidence
intervals (CI) as measures of lung cancer risk associated with
single or combined genotypes in nonsmokers and ever-smok-
ers separately. For smokers, adjustment was also made for
differences in the amount smoked in pack-years. Differences
in level of activities of the enzymes between groups were
compared using analysis of covariance adjusted for sex and
smoking as appropriate.
Statistical analyses were performed using SPSS for
Windows version 11.0 statistical package (SPSS, Chicago,
IL). The differences were considered significant at p  0.05.
RESULTS
There were 240 patients with lung cancer and 240
age-matched healthy controls. The characteristics of these
subjects by smoking habits are shown in Table 1. Among
ever-smokers, the number of pack-years smoked was signif-
icantly less in the controls compared with the patients.
The Val allele frequency of the MnSOD gene occurred
in 86% of healthy controls and 88% of patients with lung
cancer. The frequency of the C allele of the catalase gene was
95% of healthy controls and patients with lung cancer. There
was no significant difference in the allele distribution be-
tween patients and healthy controls (Table 2). Among control
subjects and patients, the frequency distributions of the
MnSOD and catalase genotypes were in Hardy-Weinberg
equilibrium.
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Because of the absence of homozygous variant AlaAla
genotype in any of the patients and its appearance in only
2.9% of controls, the AlaAla genotype was combined with
ValAla genotype in the analysis of the risk for lung cancer.
The TT genotype of catalase polymorphism did not occur in
controls but did occur in 0.9% of patients; this was combined
with CT genotype in the analysis. There were also no signif-
icant differences in allele and genotype frequencies of
MnSOD and catalase polymorphisms between healthy con-
trols and patients with lung cancer classified according to
tumor cell type (Table 2). No significant increase or decrease
in risk of lung cancer was found among those with combined
heterozygous and homozygous variant genotypes of MnSOD
and catalase between healthy controls and patients with lung
cancer classified according to tumor cell type (Table 3), or
between nonsmokers and ever-smokers (Table 4).
No difference was found for the levels of both SOD and
catalase activity among various genotypes within controls
and within patients. There was a tendency toward greater
SOD activity in carriers of the MnSOD-Ala16 allele than in
carriers of the homozygotes for the MnSOD-Val16 allele
both in controls and patients with lung cancer, although it did
not reach statistical significance. However, carriers of the
MnSOD-Ala16 allele showed significantly greater SOD ac-
tivity than carriers of the homozygotes for the MnSOD-Val16
allele in patients with adenocarcinoma (p  0.05) (Table 5).
Smoking had also no influence on the activity levels within
controls and within patients, irrespective of genotypes. How-
TABLE 1. Characteristics of Study Subjects by Smoking Groups
Nonsmoker Ever-smokers Total
Controls Patients Controls Patients Controls Patients
N 128 115 112 125 240 240
Male 52 (40.6) 35 (30.4) 107 (95.5) 117 (93.6) 159 (66.3) 152 (63.3)
Age (yrs) 52.2  12.8 51.8  11.0 57.9  11.8 59.1  11.6 54.8  12.6 55.6  11.9
Pack-years smoked NA NA 36.0  24.8 46.2  36.3a NA NA
Cell typeb NA NA NA
Squamous cell 7 (6.1) 24 (20.2) 31 (13.2)
Adenocarcinoma 78 (67.8) 57 (47.9) 135 (57.7)
NSCLCc 17 (14.8) 30 (25.2) 47 (20.1)
Othersd 13 (11.3) 8 (6.7) 21 (9.0)
a p  0.05 for differences between healthy controls and patients with lung cancer by 2 test or t test.
b Information not available for six patients.
c Cases diagnosed by cytological examination for which insufficient morphological features precluded definitive tumor subtyping.
d Included cases of large cell and small cell carcinoma.
NA, Not applicable; NSCLC, non-small cell lung cancer.
TABLE 2. Distribution of Genotype and Allele Frequencies
Gene Controls All Patients Adenocarcinoma Squamous NSCLC
MnSOD (N) 239 234 132 31 46
Genotype
ValVal 180 (75.3) 176 (75.2) 103 (78.0) 24 (77.4) 33 (71.7)
ValAla 52 (21.8) 58 (24.8) 29 (22.0) 7 (22.6) 13 (28.3
AlaAla 7 (2.9) 0 0 0 0
ValAla  AlaAla 59 (24.7) 58 (24.8) 29 (22.0) 7 (22.6) 13 (28.3)
Allele
Val 412 (86.2) 410 (87.6) 235 (89.0) 55 (88.7) 79 (85.9)
Ala 66 (13.8) 58 (12.40 29 (11.0) 7 (11.3) 13 (14.1)
Catalase (N) 240 230 130 28 47
Genotype
CC 217 (90.4) 209 (90.9) 116 (89.2) 26 (92.9) 46 (97.9)
CT 23 (9.6) 19 (8.3) 13 (10.0) 2 (7.1) 0
TT 0 2 (0.9) 1 (0.8) 0 1 (2.1)
CT  TT 23 (9.6) 21 (9.2) 14 (10.8) 2 (7.1) 1 (2.1)
Allele
C 457 (95.2) 437 (95.0) 245 (94.2) 54 (96.4) 92 (97.9)
T 23 (4.8) 23 (5.0) 15 (5.8) 2 (3.6) 2 (2.1)
NSCLC, non-small cell lung cancer.
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ever, patients with adenocarcinoma but not non-adenocarci-
noma had significantly lower levels of erythrocyte SOD and
catalase activity compared with healthy controls in those with
ValVal genotype of MnSOD gene and CC genotype of
catalase gene (Table 5). Patients with non-adenocarcinoma
showed significantly lower levels of erythrocyte SOD activity
compared with controls carrying the MnSOD-Ala16 allele.
There was no significant change in catalase activity in pa-
TABLE 3. Odds Ratios (OR) for the MnSOD Val16Ala and Catalase C-262T Polymorphisms
Crude Adjusted for age, sex and smoking
Genotype Patients/controls OR p value OR P value
MnSOD Val16Ala
Total
ValVal 176/180 1.0 1.0
ValAla  AlaAla 58/59 1.01 (0.66–1.53) 0.98 1.00 (0.66–1.52) 0.99
Adenocarcinoma
ValVal 103/180 1.0 1.0
ValAla  AlaAla 29/59 0.86 (0.52–1.42) 0.56 0.85 (0.51–1.42) 0.54
Squamous
ValVal 24/180 1.0 1.0
ValAla  AlaAla 7/59 0.89 (0.36–2.17) 0.80 0.91 (0.37–2.28) 0.85
NSCLC
ValVal 33/180 1.0 1.0
ValAla  AlaAla 13/59 1.20 (0.59–2.43) 0.61 1.19 (0.58–1.43) 0.64
Non-adenocarcinoma
ValVal 71/180 1.0 1.0
ValAla  AlaAla 25/59 1.07 (0.62–1.85) 0.80 1.07 (0.62–1.86) 0.80
Catalase C-262T
Total
CC 209/217 1.0 1.0
CT  TT 21/23 0.95 (0.51–1.76) 0.87 0.97 (0.52–1.80) 0.91
Adenocarcinoma
CC 116/217 1.0 1.0
CT  TT 14/23 1.14 (0.56–2.30) 0.72 1.14 (0.56–2.32) 0.71
Squamous
CC 26/217 1.0 1.0
CT  TT 2/23 0.73 (0.16–3.26) 0.68 0.88 (0.19–4.15) 0.87
NSCLC
CC 46/217 1.0 1.0
CT  TT 1/23 0.21 (0.03–1.56) 0.13 0.21 (0.03–1.63) 0.14
Non-adenocarcinoma
CC 89/217 1.0 1.0
CT  TT 6/23 0.64 (0.25–1.61) 0.34 0.70 (0.27–1.81) 0.47
TABLE 4. Risk Associated with Polymorphisms of MnSOD and Catalase Genes
Nonsmokers Ever smokers
Controls Patients Adjusted ORa Controls Patients Adjusted ORa
Genotype n (%) n (%) (95% CI) n (%) n (%) (95% CI)
MnSOD
ValVal 98 (77.2) 86 (77.5) 1 82 (73.2) 90 (73.2) 1
ValAla  AlaAla 29 (22.8) 25 (22.5) 0.80 (0.41–1.56) 30 (26.8) 33 (26.8) 1.02 (0.56–1.88)
Catalase
CC 115 (89.9) 103 (91.2) 1 102 (91.1) 106 (90.6) 1
CT  TT 13 (10.2) 10 (8.8) 0.77 (0.31–1.94) 10 (8.9) 26 (9.4) 1.14 (0.46–2.88)
a Adjusted for sex and for pack-years of smoking in smokers.
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tients with non-adenocarcinoma compared with controls, ir-
respective of genotypes. There was also no relationship
between SOD or catalase activity and the clinical stages
(stages IIIA, B, and IV) of lung cancer among different
genotypes of MnSOD and catalase in patients with lung
cancer (data not shown).
DISCUSSION
In this study, we did not find any association between
genetic polymorphisms of MnSOD (Val16Ala) and catalase
(C to T substitution) and risk of lung cancer in the Chinese
population in Hong Kong. However, we found that the
frequencies of Val allele of MnSOD gene6,7,10 and C allele of
catalase gene11 were much higher than those reported for
Caucasian populations. The frequencies of MnSOD ValVal
genotype of 75.3%, ValAla 21.8%, and AlaAla 2.9% in our
population were similar to those reported for the populations
in Japan, China, and Taiwan.5,8,9 The corresponding figures in
the United States population are 31%, 45%, and 24%, respec-
tively,6 similar to another study performed in the same
country.10 Catalase CC genotype was found in 90% of our
healthy controls, compared with 41.4% in Swedish men, but
that study has the very small sample size of 29 subjects.11
Most of the literature on genetic susceptibility to lung
cancer has focused on those regulating phase I and phase II
enzymes. Fewer studies have been performed on those reg-
ulating the antioxidant enzymes, such as MnSOD6–9, and so
far none have been performed on catalase. Wang et al.
demonstrated an increased risk of lung cancer with OR of 1.4
(95% CI, 1.11 to 1.76) in those with ValVal genotype6 and an
OR of 2.14 (95% CI, 1.52-3.01) in those with asbestos
exposure and ValVal genotype7 in the United States popula-
tion. The increased risk of lung cancer was explained by
decreased removal of reactive oxygen species because of
lower efficiency of MnSOD transport into mitochondria in
those with the Val allele,6 and MnSOD may also have tumor
suppressor activity.17 The same allele was not associated with
an increase in lung cancer risk in Taiwan Chinese8 and in a
Chinese population exposed to PAH-rich coal combustion
emissions.9 However, the Ala variant was found to be asso-
ciated with increased risk of breast cancer in two studies.10,18
However, the low frequency of the MnSOD Ala variant and
catalase T variant may explain why MnSOD and catalase
polymorphisms are not associated with an increased lung
cancer risk in our study.
Previous studies have demonstrated a general trend of
decrease in various antioxidants such as selenium,19 vitamins
A and E,20 SOD,21 GPx,19 and glutathione-S-transferase19 in
blood obtained from patients with lung cancer compared with
controls. Surgical removal of lung cancer results in augmen-
tation in plasma total radical-trapping antioxidant parameters
because of unidentified antioxidant components and protein
sulfhydryl groups, reflecting the relief of oxidative stress
caused by the malignant tumors.22 Therefore, our finding of
diminished erythrocyte SOD activity in patients with lung
cancer compared with controls might reflect increased oxida-
tive stress in the presence of lung tumors. Chronic inflam-
mation has also been suggested to contribute to lung carci-
nogenesis23, and inflammatory cell infiltration appeared
abundantly in the direct vicinity of resected lung tumors.24
The extent of inflammation was also found to significantly
affect the antioxidant status in lung cancer.25,26
Functional polymorphisms of both MnSOD and cata-
lase genes seem to exist. The ValVal genotype of the MnSOD
Val16Ala signal sequence polymorphism is implicated in
decreased efficiency of MnSOD transport into target mito-
chondria.5 Consistent with this report, we found significantly
higher SOD activity in carriers of the MnSOD-Ala16 allele
than in carriers of the homozygotes for the MnSOD-Val16
allele in patients with adenocarcinoma. The T allele of the
catalase C-262T promoter polymorphism is associated with
higher catalase activity level,11 which was not found in our
study. We found significant reduction in the level of eryth-
rocyte SOD and catalase activity in all patients with lung
cancer but a significant reduction in erythrocyte catalase
activity only in patients carrying CC genotype of catalase
gene with adenocarcinoma. The finding of decreased eryth-
rocyte SOD and catalase activity in patients with adenocar-
cinoma in the current study suggests less efficient conversion
of superoxide into hydrogen peroxide, together with de-
creased removal of the latter, resulting in accumulation of
ROS. However, one critical question is whether the signifi-
cantly lower levels of activity of erythrocyte SOD and cata-
lase are causally related to lung cancer or merely the conse-
TABLE 5. Erythrocyte Activity Levels of SOD and Catalase
Genotype Controls All patients Adenocarcinoma Non-adenocarcinoma
SOD activity (U/g Hb)a
MnSOD n  234 n  216 n  122 n  88
ValVal 63.0  29.2 (175) 51.0  48.8b (160) 47.0  42.8b (95) 57.0  56.3 (63)
ValAla  AlaAla 69.0  35.1 (59) 58.0  54.8 (56) 75.0  63.6c (27) 39.0  37.1b (25)
Catalase activity (U/g Hb)a
Catalase n  235 n  215 n  121 n  89
CC 0.034  0.026 (214) 0.025  0.035b (196) 0.021  0.029b (107) 0.029  0.041 (85)
CT  TT 0.026  0.012 (21) 0.030  0.028 (19) 0.030  0.032 (14) 0.024  0.016 (4)
a Values are mean  standard deviation (n).
b p  0.05 for comparison between patients with lung cancer and controls using analysis of variance adjusted for age, sex, and smoking.
c p 0.05 for comparison between ValAla AlaAla and ValVal genotypes within a group using analysis of variance adjusted for age, sex, and smoking.
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quence of carcinogenesis. Our current findings suggest that
the lower levels of erythrocyte SOD activity in patients with
lung cancer are likely the consequence of the disease process
rather than a predisposing event in Hong Kong Chinese
patients. To the best of our knowledge, this is the first
case-control study of MnSOD Val16Ala and catalase C-262T
polymorphisms and their enzyme activity as they relate to
human lung cancer of different subtypes, and the findings
may be a local phenomenon restricted to Hong Kong or
Southern Chinese with lung cancer.
The limitation of our study is that we have only
matched our controls with the patients on age but not on
pack-years of smoking, which was statistically adjusted in the
analyses as appropriate. Our sample size is relatively small
for some genotype distributions after stratification by smok-
ing, overall TNM staging, or tumor cell types, and conse-
quently has low power. As the frequencies of Ala allele of
MnSOD gene and T allele of catalase gene are very low in
our population, a very large sample would be required to give
adequate power, and this would be not economically feasible.
We also evaluated only the MnSOD Val16Ala and catalase
C-262T polymorphisms, not other polymorphisms that may
be relevant to lung cancer susceptibility. Additionally,
MnSOD and catalase may only contribute partially to the
processing of ROS; polymorphisms of other genes not eval-
uated in this study may also play a role in cellular ROS
production or removal.
In conclusion, we found no significant differences in
allele and genotype frequencies of MnSOD and catalase
polymorphisms between healthy controls and patients with
lung cancer classified according to tumor cell type. The
genotype distributions of the MnSOD Val16Ala and catalase
C-262T polymorphisms among our patients with lung cancer
and controls differed clearly from that reported for Caucasian
populations. Collectively, our findings do not support the
notion that polymorphisms of these two key antioxidant
enzymes confer genetic susceptibility of lung cancer in Hong
Kong Chinese. The decrease in the levels of SOD and
catalase activity that we identified in erythrocytes of patients
with different subtypes of lung cancer is indicative of dys-
function of oxidant/antioxidant defense mechanisms in pa-
tients with lung cancer, although it cannot be distinguished
whether this decrease in antioxidant enzyme activity is a
pathogenic factor. Additional studies are needed before the
significance of the various components of the antioxidant
machinery of the lung is elucidated in the context of patho-
genesis of lung cancer and its progression.
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